Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00743522 · ClinicalTrials.gov registry record
Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication
A clinical trial of Shock, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 1,670
- Enrollment target
- 1
- Study location
NCT00743522: Completed study of Shock, sponsored by Abbott Medical Devices.
NCT00743522 is a study of Shock that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,670 participants, above the 296-participant average among 9 other Shock trials with a reported enrollment target (464% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00743522, a study of Shock, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 1,670 participants
- Enrollment target
- 1
- Study location
Study Summary
Although shock therapy is effective in terminating ventricular tachycardia (VT), it can be painful to the patient and repetitive shocks can decrease a patient's quality of life. Previous studies have suggested that one or more sets of aggressive device parameter settings may reduce the total number of shocks in primary prevention patients. In addition to shock therapies, antitachycardia pacing (ATP) is also available in ICDs to treat VT. The PROVIDE trial aims to prospectively study the effect of high detection rates, prolonged detection intervals, aggressive SVT discriminators, and extensive ATP therapy in prolonging the time to first shock in primary prevention patients.
Conditions Studied
Interventions
- DEVICE ICD/ CRT-D
Study Locations (1)
Texas
- Hall-Garcia Cardiology Associates - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,670 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-12 |
What the finished NCT00743522 record still lists
NCT00743522 is an observational study that tracks outcomes without assigning an intervention. Its 1,670 participants enrollment target places it among the larger protocols in the corpus, above the 296-participant average among 9 other Shock trials with a reported enrollment target (464% higher).
The record links to 1 condition, with Shock appearing as the primary indexed condition, and to 1 intervention - of which ICD/ CRT-D is the first listed.
NCT00743522 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00743522 about?
NCT00743522 is a clinical study titled "Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication". Although shock therapy is effective in terminating ventricular tachycardia (VT), it can be painful to the patient and repetitive shocks can decrease a patient's quality of life. Previous studies have suggested that one or more sets of aggressive device parameter settings may reduce the total number ...
What is the current status of trial NCT00743522?
This trial is currently completed. The enrollment target is 1,670 participants. The study started on 2008-09. Estimated completion is 2011-12.
What conditions does trial NCT00743522 study?
This clinical trial studies the following conditions: Shock.
What interventions are being tested in trial NCT00743522?
The interventions under investigation include: ICD/ CRT-D (DEVICE).
Who is sponsoring clinical trial NCT00743522?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00743522 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00743522's enrollment target sits among peer trials
1,670 1st of 9 higher than 9 of 9 other Shock trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Shock trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Stroke Volume in Shock Using Echocardiography Versus Bioreactive Impedance
RECRUITING
-
Resuscitative TEE Collaborative Registry
RECRUITING
-
Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning
RECRUITING · NA
-
Central Line Study
RECRUITING · Phase 4
-
Vasoactive Drugs in Intensive Care Unit
RECRUITING · Phase 4
-
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04852887 · 1,670 participants · Phase 3
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- NCT06644625 · 1,665 participants
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- NCT06034405 · 1,663 participants
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
- NCT06376565 · 1,680 participants · NA
Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia